Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

miDiagnostics Secures €30 Million Series D Funding Round Led by Thermo Fisher Scientific to Advance an Innovative Sterility Test and Other Quality Control Tests for use in the BioPharma Industry.

Leuven, Belgium – December 4th, 2024 – miDiagnostics is pleased to announce the completion of a €30 million Series D funding round, led by Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science. This investment will accelerate the development of a groundbreaking sterility test for batch release and related quality control tests for the BioPharma Industry, utilizing miDiagnostics’ proprietary qPCR technology.

European HealthTech Innovation Needs a Lifeline – Join the Conversation to Drive Change

Ghent, Belgium, 4 December 2024 – European health technology (HealthTech) is at a critical crossroad. Despite groundbreaking research, a thriving startup scene and ambitious talent, the sector struggles to translate innovation into actionable impact. Challenges such as regulatory restrictions, fragmented markets, and funding gaps are slowing progress, while the clock is ticking and other regions of the world are surging ahead.

Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis.

Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF. ● New financing will accelerate preclinical development of Refoxy’s lead program in IPF as well as the expansion of its platform to additional age-related indications.

QbD Group announces acquisition of SciencePharma,strengthening global regulatory and quality expertise

Antwerp, Belgium / Warsaw, Poland – December 4, 2024 – QbD Group and SciencePharma have reached an agreement for QbD Group to acquire SciencePharma. The deal is expected to close by early 2025, pending antitrust clearance.

4Tissue Raises €2M to Advance Groundbreaking Breast Tissue Replacement Technology

Ghent, October 23, 2024 — 4Tissue, a pioneering biotech company revolutionizing regenerative medicine with its cutting-edge, bioresorbable hydrogel tissue mimic has successfully completed a €2M seed funding round including equity investment and non-dilutive grants. Led by three prominent female investors from the life science and business sectors, this funding will enable 4Tissue to accelerate the clinical development of its innovative platform. This investment underscores the transformative potential of 4Tissue in women’s health.

ONTOFORCE unveils DISQOVER 7: the next generation knowledge discovery platform

ONTOFORCE Achieves ISO 27001:2022 Certification: A Milestone in Information Security and Trust

Anacura acquires OHMX.bio, adding multi-omics for drug discovery and diagnostics to its services

Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.

Axithra Strengthens its Board of Directors

The appointments of Dr. Alain Pluquet as Chairman of the Board and Mr. Michael Tillmann as Independent Director brings extensive industrial expertise to help develop Axithra’s long-term strategy

V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors

V-Bio Ventures portfolio company Protealis secures EUR 22 million in oversubscribed B round funding to propel sustainable plant protein seed solutions

Protealis, a leading innovator in seed solutions for sustainable plant proteins based in Ghent, Belgium, proudly announced today the successful completion of its B-Round funding, raising a substantial EUR 22 million.

QbD Chair for Precision Oncology Research in Glioblastoma extended for three years

The QbD Chair supports the research of Professor Frederik De Smet on glioblastoma, an aggressive form of brain cancer. Behind the establishment of the Chair lies a personal story.

V-Bio Ventures-funded Tanai Therapeutics develops first-in-class therapeutics for obesity

VIB, Flanders’ leading life sciences institute, together with lead investor V-Bio Ventures has launched a new spin-off company based on research at the VIB-UGent Center for Inflammation Research. With an initial seed financing round supported by V-Bio Ventures, Qbic and VIB, the spin-off company is entering the obesity space with an entirely novel therapeutic approach.

Obulytix is developing a revolutionary solution for antibiotic resistance

Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The innovative, phage lysin-based platform – leveraging the power of artificial intelligence – attracted a significant four-million-euro investment from Boehringer Ingelheim Venture Fund, Qbic, and Gemma Frisius Fund.

Azalea Vision announces first on-eye test of ALMA, its revolutionary smart contact lens

In a significant milestone, Azalea Vision, pioneering start-up on a mission to revolutionize the treatment of ocular disorders, announces the successful demonstration of ALMA Lens, the first functional prototype of the Azalea smart contact lens’ platform.